CoVepiT / OSE Immunotherapeutics - LARVOL DELTA

COVEPIT 3: To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: OSE Immunotherapeutics; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVEPIT 3: To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults (clinicaltrials.gov) - P1; N=48; Not yet recruiting; Sponsor: OSE Immunotherapeutics

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

[VIRTUAL] CoVepiT, a Second-Generation COVID-19 Vaccine with a Multi-Target Approach Focused on CD8 T-Cell Epitopes (PEGS 2021) - "CoVepiT has potential for an universal vaccine against coronaviruses (including all previous, currently circulating and future mutated SARS-CoV-2 variants). The technology is based on optimized CD8 T-cell epitopes:Against 11 SARS-CoV-2 proteins (S, M, N, NSPs and accessory protein)In stable (non-mutated) SARS-CoV-2 genome (analysis of > 300 000 sequences, elimination of epitopes in « hotspots » mutations region)High homology with previous SARS-CoV-1 (90-100%) and MERS (60-90%)High HLA A,B,C coverage, hence no HLA genotype restrictionImmunodominant epitopes selected based on positive response in COVID-19 convalescent versus unexposed subjects (n=120 asymptomatic, moderate and severe patients)"

Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD8

"Bonne idée et on attend le deal special variant Covepit d’ ose Immunotherapeutics $ose" (@benjamin0290)

OSE Immunotherapeutics Reports First Half 2020 Results and Corporate Update (GlobeNewswire) - "CoVepiT, a 2nd generation multi-target vaccine against COVID-19, developed using SARS-CoV-2 optimized neo-epitopes....A Phase 1/2 clinical study evaluating CoVepiT's efficacy is expected to be initiated by the end of 2020 or early 2021."

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease

OSE Immunotherapeutics Receives €200,000 from Nantes Metropole to Develop CoVepiT, its COVID-19 Prophylactic Vaccine Program (GlobeNewswire) - "OSE Immunotherapeutics...today announced it will receive a grant of up to €200,000 from Nantes Metropole, the metropolitan area of Nantes community, dedicated to the development of a prophylactic vaccine against the pandemic virus SARS-CoV-2. This funding was awarded as part of the Metropolitan Fund to Support Health Innovations Linked to the COVID-19 Health Crisis, a €1 million fund created by Nantes Metropole for health innovations to address the COVID-19 health crisis....Research program aims to develop a prophylactic vaccine focused on memory T cells and based on a multiepitope- peptide approach..."

Grant • Infectious Disease • Novel Coronavirus Disease